山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (10): 40-45.doi: 10.6040/j.issn.1671-7554.0.2018.1013
• • 上一篇
崔巍,张玉娟
CUI Wei, ZHANG Yujuan
摘要： 循环肿瘤细胞检测作为肿瘤无创和实时疗效监测的手段,具有潜在的临床应用前景,但由于其本身的特性,在其检测技术方面仍具有挑战。就循环肿瘤细胞(CTC)的检测现状和面临的挑战做一论述,以期更好开展临床工作。
中图分类号:
| [1] Hunter K, Amin R, Deasy S, et al. Genetic insights into the morass of metastatic heterogeneity[J]. Nat Rev Cancer, 2018, 18(4): 211-223. [2] Hiley C, de Bruin E, McGranahan N, et al. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine[J]. Genome Biol, 2014, 15(8): 453-465. [3] Woo D, Yu M. Circulating tumor cells as “liquid biopsies” to understand cancer metastasis[J]. Transl Res, 2018. doi:10.1016/j.trsl.2018.07.003. [4] Russo G, Bier S, Hennenlotter J, et al. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer[J]. BJU Int, 2018, 122(1): 152-159. [5] 乔雪峰, 张玉娟, 崔巍. 循环肿瘤细胞致肿瘤血行转移研究进展[J]. 协和医学杂志, 2014,5(3): 331-334. [6] Ignatiadis M, Lee M, Jeffrey S. Circulating tumor cells and circulating tumor DNA: Challenges and opportunities on the path to clinical utility[J]. Clin Cancer Res, 2015, 21(21): 4786-4800. [7] Ortiz V, Yu M. Analyzing circulating tumor cells one at a time[J]. Trends Cell Biol, 2018. doi:10.1016/j.tcb. 2018.05.004. [8] 陈锋, 吴玥, 崔巍. 液体活检走进临床有多远[J]. 中华医学杂志, 2017, 97(34): 2641-2645. [9] Zhang Y, Wang F, Ning N, et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer[J]. Int J Cancer, 2015, 136(5): 1228-1233. [10] Chen Q, Ge F, Cui W, et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging[J]. Clin Chim Acta, 2013, 419: 57-61. doi:10.1016/j.cca.2013.01.015. [11] Ning N, Zhan T, Zhang Y, et al. Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization[J]. Clin Chim Acta, 2014, 433(10): 69-75. [12] Liu H, Triboulet M, Zia A, et al. Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection[J]. NPJ Genom Med, 2017, 2: 34-46. doi: 10.1038/s41525-017-0034-3. [13] Cho H, Kim J, Song H, et al. Microfluidic technologies for circulating tumor cell isolation[J]. Analyst, 2018, 143(13): 2936-2970. [14] Paoletti C, Cani A, Larios J, et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms[J]. Cancer Res, 2018, 78(4): 1110-1122. [15] Alva A, Friedlander T, Clark M, et al. Circulating tumor cells as potential biomarkers in bladder cancer[J]. J Urol, 2015, 194(3): 790-798. [16] Miller M, Robinson P, Wagner C, et al. The parsortixTM cell separation system-a versatile liquid biopsy platform[J]. Cytometry A, 2018. doi: 10.1002/cyto.a.23571. [17] Tong B, Xu Y, Zhao J, et al. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy[J]. Oncotarget, 2017, 8(49): 86615-86624. [18] Wang W, Wan L, Wu S, et al. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis[J]. Cell Oncol(Dordr), 2018. doi:10.1007/s13402-018-0386-4. [19] Qi L, Xiang B, Wu F, et al. Circulating tumor cells undergoing emt provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma[J]. Cancer Res, 2018, 78(16): 4731-4744. [20] Jin X, Zhu L, Qian K, et al. Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review[J]. Oncotarget, 2017, 8(14): 23130-23141. [21] Lee Y, Guan G, Bhagat A. ClearCell® FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells[J]. Cytometry A, 2018. doi: 10.1002/cyto.a.23507. [22] Winer-Jones J, Vahidi B, Arquilevich N, et al. Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell[J]. PLoS One, 2014, 9(1): e86717. doi:10.1371/journal.pone.0086717. [23] Hüsemann Y, Geigl J, Schubert F, et al. Systemic spread is an early step in breast cancer[J]. Cancer Cell, 2008, 13(1): 58-68. [24] Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients[J]. Cancer Cell, 2013, 23(5): 573-581. [25] Leroy S, Benzaquen J, Mazzetta A, et al. Circulating tumour cells as a potential screening tool for lung cancer(the AIR study): protocol of a prospective multicentre cohort study in France[J]. BMJ Open, 2017, 7(12): e018884. [26] Ilie M, Hofman V, Long-Mira E, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10): e111597. doi:10.1371/journal.pone.0111597. [27] Chiang A, Massagué J. Molecular basis of metastasis[J]. N Engl J Med, 2008, 359(26): 2814-2823. [28] Sandri M, Zorzino L, Cassatella M, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery[J]. Ann Surg Oncol, 2010, 17(6): 1539-1545. [29] Zhang Q, Shan F, Li Z, et al. A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer[J]. J Transl Med, 2018, 16(1): 171-182. [30] Zhang Z, Xiao Y, Zhao J, et al. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer[J]. Respirology, 2016, 21(3): 519-525. [31] Sparano J, O'Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2018. doi:10.1001/jamaoncol.2018.2574. [32] Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase iii clinical trials[J]. J Clin Oncol, 2018, 36(6): 572-580. [33] Hong X, Sullivan R, Kalinich M, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy[J]. Proc Natl Acad Sci USA, 2018, 115(10): 2467-2472. [34] Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor dna as liquid biopsy[J]. Cancer Discov, 2016, 6(5): 479-491. [35] Gkountela S, Aceto N. Stem-like features of cancer cells on their way to metastasis[J]. Biol Direct, 2016, 11: 33-46. doi:10.1186/s13062-016-0135-4. |
| [1] | 耿晨,杨阳,赵月,刘浩冉,晁岚. 子宫腺肌病中差异基因筛选及Wilms tumor-1的表达[J]. 山东大学学报 (医学版), 2021, 59(4): 79-86. |
| [2] | 杨似玉,闫晓娜,彭靖,张杰,王永星,张欣烨,张书芳. 郑州市两城区大气PM2.5中金属、类金属污染特征及健康风险评估[J]. 山东大学学报 (医学版), 2021, 59(12): 70-77. |
| [3] | 徐有伟,周洪雷,任冬梅,娄红祥,沈涛. 潺槁木姜子地上部位化学成分[J]. 山东大学学报（医学版）, 2016, 54(3): 45-49. |
| [4] | 陈文标, 喻祥琪, 戴勇. Alport综合征iPSCs差异性表达新小核糖核苷酸的分析[J]. 山东大学学报（医学版）, 2015, 53(9): 80-85. |
| [5] | 王梅竹, 曹煜, 赵亮, 徐小珊, 张佩芳, 吕倩, 白逢彦, 康颖倩. 贵州地区临床酵母菌种类组成和分布[J]. 山东大学学报（医学版）, 2014, 52(8): 94-97. |
| [6] | 王志刚，姜彬，孟庆虎，郝晓光，丁璇，李纪森 . 人脑胶质瘤干细胞的分离和脑瘤浸润动物模型的建立[J]. 山东大学学报(医学版), 2012, 50(5): 60-. |
| [7] | 李芸1，王红2，王波1，许永广1，张孟元1，王公明1. 新生大鼠前扣带皮层神经元的原代培养[J]. 山东大学学报(医学版), 2011, 49(5): 54-57. |
| [8] | 赵丽1，温红玲1，侯霄煜2，蒲双双1，宋艳艳1，许洪芝1，李凤琴3. 抗脱氧雪腐镰刀菌烯醇单克隆抗体的制备及鉴定[J]. 山东大学学报(医学版), 2010, 48(12): 146-149. |
| [9] | 张春华sup>,温泽清,朱勇,陈秀玲 . 人骨髓造血干细胞体外扩增培养及其生物学特性研究[J]. 山东大学学报(医学版), 2006, 44(10): 993-997. |
|
||
